AbolerIS Pharma Closes a Round of €27 Million Led by Caixa Capital

AbolerIs Pharma obtains financing to develop its new drug. The Belgian biopharmaceutical company has obtained €27.3 million from a Series A financing round led by Criteria Bio Ventures, the specialized fund of Caixa Capital Risc.

Sound Bioventures, Sfpim, Wallonie Entreprendre, Sambrienvest, Sudinvest, and existing investors Newton Biocapital and Turenne Capital also participated in the round.

AbolerIS Pharma highlights that the resources will allow them to accelerate the clinical development of their new drug, a monoclonal antibody with the potential to establish a new standard treatment for various autoimmune diseases.

Read more about AbolerIS Pharma’s latest financing round and find the most important financial news of the day with the Born2Invest mobile app.

AbolerIS Pharma manager highlights the the new therapy

Pablo Cironi, director of the Criteria Bio Ventures fund at Caixa Capital Risk, stated that “AbolerIS Pharma proposes a radical change in the approach to the treatment of autoimmune diseases such as rheumatoid arthritis, and we are supporting a team of renowned scientific founders with decades of experience. of experience in immunology together with an experienced management team in the biotech sector,” according to the manager.

Ignacio Anegon and Carole Guillonneau, co-founders of AbolerIs Pharma, have highlighted the new therapy “which aims to restore immune balance and attack the underlying causes of autoimmune and inflammatory diseases, offering hope for lasting remission and less dependence on immunosuppressive medications,” as applauded by the pharmaceutical company’s top officials.

Caixa Capital Risc currently manages more than €200 million and is part of the CriteriaCaixa group

AbolerIS Pharma is a biopharmaceutical company focused on revolutionizing immunotherapy for autoimmune and inflammatory diseases. Through an innovative antibody therapy directed against the novel target CD45RC, AbolerIS Pharma aims to restore immune balance and achieve long-lasting remission in patients with conditions such as rheumatoid arthritis.

For its part, Caixa Capital Risc is a venture capital company that, through its specialized fund Criteria Bio Ventures, invests in biotechnology and health sciences companies. Criteria Bio Ventures invests in international companies, focusing mainly on Spain, Portugal, and the rest of Europe.

Caixa Capital Risc currently manages more than 200 million euros and is part of the CriteriaCaixa group. The fund has been investing since 2007 and its portfolio companies have gone public or been acquired by renowned companies such as Astra Zeneca, Boehringer Ingelheim, Vifor Pharma, Qiagen, Apple, Meta, Airbnb, Vente-Privee, Pernod Ricard and Repsol, among others. 

__

(Featured image by Walkerssk via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.